Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2019 ASCO Annual Meeting!


Session: Harnessing Technology in Symptoms and Survivorship

Type: Clinical Science Symposium

Time: Saturday June 1, 8:00 AM to 9:30 AM

Location: S102

Prediction of treatment (tx)-induced fatigue in breast cancer (BC) patients (pts) using machine learning on genome-wide association (GWAS) data in the prospective CANTO cohort.

Sub-category:
Late and Long-Term Effects

Category:
Symptoms and Survivorship

Meeting:
2019 ASCO Annual Meeting

Abstract No:
11515

Citation:
J Clin Oncol 37, 2019 (suppl; abstr 11515)

Author(s): Sangkyu Lee, Joseph O. Deasy, Jung Hun Oh, Antonio Di Meglio, Sandrine Boyault, Marina Rousseau-Tsangaris, Celine Besse, Emilie Thomas, Anne Boland-Augé, Paul H. Cottu, Olivier Tredan, Christelle Levy, Anne-Laure Martin, Sibille Everhard, Patricia A. Ganz, Ann H. Partridge, Stefan Michiels, Jean-Francois Deleuze, Fabrice Andre, Ines Maria Vaz Duarte Luis; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan-Kettering Cancer Center, New York, NY; Institut Gustave Roussy, Villejuif, France; Centre Léon Berard, Lyon, France; Centre Léon-Bérard, Lyon, France; CNRGH, Evry, France; Fondation Synergie Lyon Cancer, Lyon, France; Institut Curie, Paris, France; Département d'Oncologie Médicale, Centre Léon Bérard, Lyon, France; Centre François Baclesse, Department of Medical Oncology, Caen, France; Unicancer, Paris, France; University of California, Los Angeles, Los Angeles, CA; Dana-Farber Cancer Institute, Boston, MA

Abstract Disclosures

Abstract:

Background: Many BC survivors report fatigue. The relevant genomic correlates of fatigue after BC are not well understood. We applied a previously validated machine learning methodology (Oh 2017) to GWAS data to identify biological correlates of fatigue induced after tx. Methods: We analyzed 3825 BC pts with GWAS data (Illumina InfiniumExome24 v 1.1) from the CANTO study (NCT01993498). The outcome of this study was post-tx fatigue 1 year after the end of primary chemotherapy/radiotherapy/surgery using the EORTC C30 fatigue subscale (overall fatigue) and the EORTC FA 12 fatigue domains (physical/emotional/cognitive). For each domain, we limited the study group to those with zero baseline fatigue and defined severe fatigue change as score increase above the third quartile. We tested univariate correlations between severe fatigue in each domain and 496539 SNPs as well as relevant clinical variables. The machine learning prediction model based on preconditioning random forest regression (PRFR) (Oh et al., 2017), was then built using the SNPs with ancestry adjusted univariate p-value < 0.001 and clinical variables with Bonferroni adjusted p-value < 0.05. The model was validated in a holdout subset of the cohort. Gene set enrichment analysis (GSEA) was performed using MetaCore to identify key biological correlates relevant to tx-induced fatigue. Results: Distinct results were found by fatigue domain (table). GSEA showed that the cognitive fatigue model SNPs included biomarkers for cognitive disorders (p = 1.6 x 10-12) and glutamatergic synaptic transmission (p = 1.6 x 10-8). Conclusions: A SNP based model had differential performance by fatigue domain, with a potential genetic role on risk and biology for tx induced cognitive fatigue. Further research to explore biomarkers of tx induced fatigue are needed.

Fatigue domainSamples
(train/holdout, N)
Event rate (%)Significant clinical variables (N)SNPs with p< 0.001
(N)
PRFR performance
AUC (p)
SNP onlySNP + clinical
Overall377/1611303090.42 (0.89)NA
Physical283/1211902770.44 (0.78)NA
Emotional515/2202132570.42 (0.96)0.42 (0.96)
Cognitive820/3511762990.59 (0.01)0.61 (0.003)

Funding Source: French National Agency for Research (ANR), Susan Komen for Cure (CCR17483507) to IVZ

 
Other Abstracts in this Sub-Category:

 

1. Osteonecrosis of the jaw in patients with cancer receiving zoledronic acid for bone metastases: SWOG S0702, NCT00874211.

Meeting: 2019 ASCO Annual Meeting Abstract No: 11502 First Author: Catherine H. Van Poznak
Category: Symptoms and Survivorship - Late and Long-Term Effects

 

2. Safety of pregnancy following breast cancer (BC) in patients (pts) carrying a BRCA mutation (mBRCA): Results of an international cohort study.

Meeting: 2019 ASCO Annual Meeting Abstract No: 11506 First Author: Matteo Lambertini
Category: Symptoms and Survivorship - Late and Long-Term Effects

 

3. Association of baseline cardiovascular risk factors and health care utilization and costs in elderly breast cancer patients enrolled in SWOG clinical trials.

Meeting: 2019 ASCO Annual Meeting Abstract No: 11508 First Author: Dawn L. Hershman
Category: Symptoms and Survivorship - Late and Long-Term Effects

 

More...